You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 12, 2024

Investigational Drug Information for Lucitanib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Lucitanib?

Lucitanib is an investigational drug.

There have been 9 clinical trials for Lucitanib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 14th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.

There are forty-two US patents protecting this investigational drug and four hundred and two international patents.

Recent Clinical Trials for Lucitanib
TitleSponsorPhase
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyClovis Oncology, Inc.Phase 1/Phase 2
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyEli Lilly and CompanyPhase 1/Phase 2
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyExelixisPhase 1/Phase 2

See all Lucitanib clinical trials

Clinical Trial Summary for Lucitanib

Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib

See all Lucitanib clinical trials

US Patents for Lucitanib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucitanib ⤷  Sign Up Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
Lucitanib ⤷  Sign Up Human anti-VEGFR-2/KDR antibodies KADMON CORPORATION, LLC (New York, NY) ⤷  Sign Up
Lucitanib ⤷  Sign Up Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.